Fluent Financial LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Fluent Financial LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 89,513 shares of the biopharmaceutical company's stock, valued at approximately $2,268,000. Pfizer makes up approximately 1.0% of Fluent Financial LLC's investment portfolio, making the stock its 28th biggest holding.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Mcdonald Partners LLC grew its position in Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $264,000. Harvey Capital Management Inc. bought a new position in Pfizer in the 4th quarter valued at approximately $544,000. ING Groep NV boosted its position in Pfizer by 48.6% during the 4th quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock worth $26,881,000 after buying an additional 331,403 shares during the period. Finally, WCM Investment Management LLC grew its holdings in Pfizer by 128.7% during the 4th quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company's stock worth $3,062,000 after acquiring an additional 65,238 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 1.2%

Shares of PFE stock traded down $0.29 on Thursday, reaching $23.11. 33,167,122 shares of the company were exchanged, compared to its average volume of 40,982,550. The company has a 50-day moving average of $23.02 and a 200-day moving average of $25.02. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $131.36 billion, a price-to-earnings ratio of 16.39, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company's quarterly revenue was down 7.8% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.44%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.